| BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair E Hatchi, K Skourti-Stathaki, S Ventz, L Pinello, A Yen, ... Molecular cell 57 (4), 636-647, 2015 | 483 | 2015 |
| Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids SJ Hill, B Decker, EA Roberts, NS Horowitz, MG Muto, MJ Worley Jr, ... Cancer discovery 8 (11), 1404-1421, 2018 | 387 | 2018 |
| BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair V Ginjala, K Nacerddine, A Kulkarni, J Oza, SJ Hill, M Yao, E Citterio, ... Molecular and cellular biology, 2011 | 285 | 2011 |
| 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade AR Aref, M Campisi, E Ivanova, A Portell, D Larios, BP Piel, N Mathur, ... Lab on a Chip 18 (20), 3129-3143, 2018 | 236 | 2018 |
| Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer PA Konstantinopoulos, W Luo, JF Liu, DC Gulhan, C Krasner, JJ Ishizuka, ... Journal of Clinical Oncology 37 (30), 2786-2794, 2019 | 204 | 2019 |
| Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial JF Liu, C Herold, KP Gray, RT Penson, N Horowitz, PA Konstantinopoulos, ... JAMA oncology 5 (12), 1731-1738, 2019 | 185 | 2019 |
| Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage SJ Hill, T Rolland, G Adelmant, X Xia, MS Owen, A Dricot, TI Zack, ... Genes & development 28 (17), 1957-1975, 2014 | 158 | 2014 |
| Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage SJ Hill, DA Mordes, LA Cameron, DS Neuberg, S Landini, K Eggan, ... Proceedings of the National Academy of Sciences 113 (48), E7701-E7709, 2016 | 148 | 2016 |
| BRCA1 is required for postreplication repair after UV-induced DNA damage S Pathania, J Nguyen, SJ Hill, R Scully, GO Adelmant, JA Marto, ... Molecular cell 44 (2), 235-251, 2011 | 143 | 2011 |
| Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer C Wan, MP Keany, H Dong, LF Al-Alem, UM Pandya, S Lazo, K Boehnke, ... Cancer research 81 (1), 158-173, 2021 | 113 | 2021 |
| BRCA1 pathway function in basal-like breast cancer cells SJ Hill, AP Clark, DP Silver, DM Livingston Molecular and cellular biology 34 (20), 3828-3842, 2014 | 55 | 2014 |
| Predictive potential of head and neck squamous cell carcinoma organoids SJ Hill, AD D'Andrea Cancer Discovery 9 (7), 828-830, 2019 | 24 | 2019 |
| Pagetoid lesions of the vulva: a collision between malignant melanoma and extramammary Paget disease SJ Hill, R Berkowitz, SR Granter, MS Hirsch International journal of gynecological pathology 27 (2), 292-296, 2008 | 22 | 2008 |
| Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid … KT Do, SJ Hill, B Kochupurakkal, JG Supko, C Gannon, A Anderson, ... Cancer Research 79 (13_Supplement), CT232-CT232, 2019 | 17 | 2019 |
| Exploiting the prevalence of homologous recombination deficiencies in high-grade serous ovarian cancer S Bouberhan, L Philp, S Hill, LF Al-Alem, B Rueda Cancers 12 (5), 1206, 2020 | 8 | 2020 |
| Endometrial Cancer Risk Among Germline BRCA1/2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps K Sorouri, F Lynce, CM Feltmate, MR Davis, MG Muto, ... JCO Precision Oncology 7, e2300290, 2023 | 5 | 2023 |
| Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling B Schröfelbauer, PK Kimes, P Hauke, CE Reid, K Shao, SJ Hill, R Irizarry, ... Proceedings of the National Academy of Sciences 120 (1), e2206751120, 2023 | 3 | 2023 |
| Abstract 368A: functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids SJ Hill, P Lizotte, NS Horowitz, MG Muto, MJ Worley, CM Feltmate, ... Cancer Research 79 (13_Supplement), 368A-368A, 2019 | 2 | 2019 |
| Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma Y Matoba, DT Zarrella, V Pooladanda, M Azimi Mohammadabadi, E Kim, ... British Journal of Cancer 130 (9), 1463-1476, 2024 | 1 | 2024 |
| Sialyl-Tn serves as a potential therapeutic target for ovarian cancer L Al-Alem, JM Prendergast, J Clark, B Zarrella, DT Zarrella, SJ Hill, ... Journal of Ovarian Research 17 (1), 71, 2024 | 1 | 2024 |
